These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 21955197)

  • 61. Novel IDH1-Targeted Glioma Therapies.
    Karpel-Massler G; Nguyen TTT; Shang E; Siegelin MD
    CNS Drugs; 2019 Dec; 33(12):1155-1166. PubMed ID: 31768950
    [TBL] [Abstract][Full Text] [Related]  

  • 62. 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft.
    Borodovsky A; Salmasi V; Turcan S; Fabius AW; Baia GS; Eberhart CG; Weingart JD; Gallia GL; Baylin SB; Chan TA; Riggins GJ
    Oncotarget; 2013 Oct; 4(10):1737-47. PubMed ID: 24077805
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The Multifunctional Role of EMP3 in the Regulation of Membrane Receptors Associated with IDH-Wild-Type Glioblastoma.
    Martija AA; Pusch S
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34067658
    [TBL] [Abstract][Full Text] [Related]  

  • 64. IDH mutations in human glioma.
    Kim W; Liau LM
    Neurosurg Clin N Am; 2012 Jul; 23(3):471-80. PubMed ID: 22748659
    [TBL] [Abstract][Full Text] [Related]  

  • 65. New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.
    Dimitrov L; Hong CS; Yang C; Zhuang Z; Heiss JD
    Int J Med Sci; 2015; 12(3):201-13. PubMed ID: 25678837
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Friend or foe-IDH1 mutations in glioma 10 years on.
    Huang LE
    Carcinogenesis; 2019 Nov; 40(11):1299-1307. PubMed ID: 31504231
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Glioblastoma with PNET-like components has a higher frequency of isocitrate dehydrogenase 1 (IDH1) mutation and likely a better prognosis than primary glioblastoma.
    Song X; Andrew Allen R; Terence Dunn S; Fung KM; Farmer P; Gandhi S; Ranjan T; Demopoulos A; Symons M; Schulder M; Li JY
    Int J Clin Exp Pathol; 2011; 4(7):651-60. PubMed ID: 22076165
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Ivosidenib, an IDH1 inhibitor, in a patient with recurrent,
    Tejera D; Kushnirsky M; Gultekin SH; Lu M; Steelman L; de la Fuente MI
    CNS Oncol; 2020 Sep; 9(3):CNS62. PubMed ID: 32716208
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Spontaneous in vitro senescence of glioma cells confirmed by an antibody against IDH1R132H.
    Stoczynska-Fidelus E; Och W; Rieske P; Bienkowski M; Banaszczyk M; Winiecka-Klimek M; Zieba J; Janik K; Rosiak K; Treda C; Stawski R; Radomiak-Zaluska A; Piaskowski S
    Anticancer Res; 2014 Jun; 34(6):2859-67. PubMed ID: 24922649
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Proteomic analysis of oligodendrogliomas expressing a mutant isocitrate dehydrogenase-1.
    Thirant C; Varlet P; Lipecka J; Le Gall M; Broussard C; Chafey P; Studler JM; Lacombe J; Lions S; Guillaudeau A; Camoin L; Daumas-Duport C; Junier MP; Chneiweiss H
    Proteomics; 2011 Nov; 11(21):4139-54. PubMed ID: 21898821
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Novel insights into the pathogenesis of gliomas based on large-scale molecular profiling approaches.
    Riemenschneider MJ; Reifenberger G
    Curr Opin Neurol; 2009 Dec; 22(6):619-24. PubMed ID: 19741528
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Metabolism, gliomas, and IDH1.
    Smeitink J
    N Engl J Med; 2010 Mar; 362(12):1144-5. PubMed ID: 20335593
    [No Abstract]   [Full Text] [Related]  

  • 73. Discovery of new small molecule inhibitors targeting isocitrate dehydrogenase 1 (IDH1) with blood-brain barrier penetration.
    Cao H; Zhu G; Sun L; Chen G; Ma X; Luo X; Zhu J
    Eur J Med Chem; 2019 Dec; 183():111694. PubMed ID: 31561044
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.
    Tateishi K; Wakimoto H; Iafrate AJ; Tanaka S; Loebel F; Lelic N; Wiederschain D; Bedel O; Deng G; Zhang B; He T; Shi X; Gerszten RE; Zhang Y; Yeh JJ; Curry WT; Zhao D; Sundaram S; Nigim F; Koerner MVA; Ho Q; Fisher DE; Roider EM; Kemeny LV; Samuels Y; Flaherty KT; Batchelor TT; Chi AS; Cahill DP
    Cancer Cell; 2015 Dec; 28(6):773-784. PubMed ID: 26678339
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes.
    Seiz M; Tuettenberg J; Meyer J; Essig M; Schmieder K; Mawrin C; von Deimling A; Hartmann C
    Acta Neuropathol; 2010 Aug; 120(2):261-7. PubMed ID: 20514489
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation.
    Calvert AE; Chalastanis A; Wu Y; Hurley LA; Kouri FM; Bi Y; Kachman M; May JL; Bartom E; Hua Y; Mishra RK; Schiltz GE; Dubrovskyi O; Mazar AP; Peter ME; Zheng H; James CD; Burant CF; Chandel NS; Davuluri RV; Horbinski C; Stegh AH
    Cell Rep; 2017 May; 19(9):1858-1873. PubMed ID: 28564604
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Gray Areas in the Gray Matter:
    van den Bent MJ; Mellinghoff IK; Bindra RS
    Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-8. PubMed ID: 32186930
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Establishment of a novel monoclonal antibody SMab-1 specific for IDH1-R132S mutation.
    Kaneko MK; Tian W; Takano S; Suzuki H; Sawa Y; Hozumi Y; Goto K; Yamazaki K; Kitanaka C; Kato Y
    Biochem Biophys Res Commun; 2011 Mar; 406(4):608-13. PubMed ID: 21352804
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Prognostic significance of IDH 1 mutation in patients with glioblastoma multiforme.
    Khan I; Waqas M; Shamim MS
    J Pak Med Assoc; 2017 May; 67(5):816-817. PubMed ID: 28507382
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Glioma immunotherapy enhancement and CD8-specific sialic acid cleavage by isocitrate dehydrogenase (IDH)-1.
    Cordner R; Jhun M; Panwar A; Wang H; Gull N; Murali R; McAbee JH; Mardiros A; Sanchez-Takei A; Mazer MW; Fan X; Jouanneau E; Yu JS; Black KL; Wheeler CJ
    Oncogene; 2023 Jun; 42(25):2088-2098. PubMed ID: 37161052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.